Introduction
Heart failure (HF) patients are older and frequently present with multiple co-morbidities. Co-morbidities worsen patient symptoms and may contribute to the progression of heart failure, increase mortality or limit the therapeutic response to treatment. Obstructive sleep apnoea (OSA) affects 2-4% of the adult population world-wide and is associated with similar risk factors to HF, meaning it is a frequent finding in HF patients, including HFrEF, HFmrEF and HFpEF. OSA has consistently been shown to be associated with hypertension, coronary artery disease, arrhythmias, heart failure, and stroke. [1] [2] A thorough understanding of the diagnosis and treatment options of OSA is of paramount importance to the practising HF clinician. Patients may present to the HF specialist having been diagnosed by a formal sleep study or may be suspected of OSA because of symptoms of snoring, reports of obstructed breathing by the sleep partner or day-time sleepiness.
OSA is caused by upper airway obstruction, usually associated with upper airway collapse. OSA manifests as intermittent airway occlusions, accompanied by consequent loss of airflow, arterial deoxygenation and arousal due to the stimulatory effects of chemoreflex firing secondary to the disturbed arterial blood gases. These obstructive apnoeas or hypopnoeas can occur throughout sleep and are somewhat irregular and are quite distinct form another sleep disordered breathing pattern seen in CHF, central sleep apnoea. [3] The mechanisms underlying the development of OSA in HF are no different to those in patients without HF, but a mixed apnoea pattern is more likely due to respiratory control system instability with subsequent oscillations of the arterial blood carbon dioxide levels (PaCO 2 ) and ventilatory drive due to lung congestion, reduced cardiac output, prolonged circulation times and elevated chemosensitivity. 
Pathophysiology
Each OSA cycle of apnoea or hyperpnoea is to an extent independent. The initiating factor is usually airway collapse causing an obstruction to airflow and consequent loss of effective breathing. Hypoxia and consequent arousal (and a surge in sympathetic activity) increases sufficiently to awaken the patient enough such that the airway is opened and effective breathing can resume. Frequent episodes of airway obstruction, hypoxia, and arousal during sleep impart significant sympathetic
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Heart Failure; Sleep Apnoea; Guidelines nervous system hyper-activation and hypertension which with hypoxaemia combine to increase the risk of ventricular arrhythmias. In addition the highly negative intra-thoracic pressure swings characteristic of increased ventilatory effort acting against a closed airway lead to worsened left ventricular after-load due to an increase in the transmural left ventricular pressure gradient. With an increasing frequency these episodes, cumulatively adversely affect the heart and contribute to the progression of HF including an increased risk for recurrent HF hospitalizations, ventricular arrhythmias and mortality. [6] Identifying heart failure patients with OSA
Given the pathophysiological and prognostic significance of OSA in patients with HF, and the overlap in the risk factors for these two conditions clinicians should be aware of the possibility of OSA affecting their HF patients. It is recommended to consider the possibility of OSA whenever a HF patient complains of sleep related symptoms, reports worsened snoring or day-time sleepiness or is admitted for decompensation or more detailed assessment. Questioning the sleep partner of a patient is also highly valuable in identifying OSA patients. Additional signs and symptoms consistent with the presence of OSA include unusual daytime sleepiness, disturbed nocturnal breathing, disrupted sleep, nocturia, morning headaches, and diminished concentration and memory. [7] OSA has traditionally been diagnosed by formal polysomnography (PSG), during an overnight sleep study in a sleep laboratory. The recent introduction of portable monitors offers an easier route to assess HF patients for the likelihood of OSA. Based on current guidelines, the PSG is diagnostic for OSA if respiratory monitoring demonstrates at least five obstructive hypoxaemic episodes per hour of sleep (or more than 15 in the absence of sleep related symptoms) and this frequency is defined as the apnoea-hypopnoea index (AHI). [8] Treatment options for OSA
The mainstay of treatment for OSA is a positive airway pressure mask which can be used in mild moderate and severe OSA. [8] The need for therapy should be discussed with the patient and if the AHI is above 15/hr then treatment is indicated to reduce this to below 15. This is a consensus recommendation and no adequately powered clinical trials have shown this improves either mortality or the risk of disease progression. Compliance with mask therapy is limited and the need for on-going therapy and the willingness of a patient to continue may depend on whether there is a noticeable improvement in sleep related or daytime sleepiness symptoms induced by therapy. There are currently three primary types of these therapies: continuous positive airway pressure (CPAP), bi-level positive airway pressure (BiPAP) in which pressure levels decrease during exhalation, and BiPAP-adaptive servoventilation (ASV) in which the two pressures change due to sensors in the device. [9] The adverse effects of ASV in HFrEF patients with predominantly central sleep apnoea mean that this therapy should be reserved only for those with predominant OSA-type sleep apnoea (see chapter on CSA). Mask based therapy should be combined with life-style changes such as weight loss in the obese, regular exercise and the avoidance of alcohol and other sedatives prior to retiring for the night. Positioning the sleeping patient head-up can also help. Custom-made oral appliances that push the mandible forward or specially designed mouth guards can assist to a limited extent. Upper airway reconstructive surgery is occasionally used in severe cases unresponsive to or intolerant of mask therapy.
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